Displaying One Session

GSK - First-line PARP inhibitor maintenance therapy in advanced ovarian cancer: improving safety outcomes and the patient experience (ID 156)

Time
17:35 - 19:05

Introduction to PARPi maintenance therapy (ID 4844)

Individualized patient care during PARPi maintenance therapy (ID 4845)

Bringing the evidence together: efficacy, safety, and quality of life (ID 4846)

Discussion  (ID 4847)